EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Astragaloside IV Inhibits NLRP3 Inflammasome-Mediated Pyroptosis via Activation of Nrf-2/HO-1 Signaling Pathway and Protects against Doxorubicin-Induced Cardiac Dysfunction

Xueheng Chen, Chao Tian, Zhiqiang Zhang, Yiran Qin, Runqi Meng, Xuening Dai, Yuanyuan Zhong, Xiqing Wei, Jinguo Zhang, Cheng Shen

Frontiers in Bioscience-Landmark · 2023

DOI: 10.31083/j.fbl2803045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Xueheng Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Jining Medical University, Clinical Medical College, Jining Medical University, 272000 Jining, Shandong, China. Hauptthemen laut MEDLINE: Pyroptosis, Heart Diseases. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Province Medical and health Science and Technology Development Program, National Nature Science Foundation of China, Jining City Science and Technology Key Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Doxorubicin (DOX) is an effective broad-spectrum antitumor drug, but its clinical application is limited due to the side effects of cardiac damage. Astragaloside IV (AS-IV) is a significant active component of Astragalus membranaceus that exerts cardioprotective effects through various pathways. However, whether AS-IV exerts protective effects against DOX-induced myocardial injury by regulating the pyroptosis is still unknown and is investigated in this study.

Methods

The myocardial injury model was constructed by intraperitoneal injection of DOX, and AS-IV was administered via oral gavage to explore its specific protective mechanism. Cardiac function and cardiac injury indicators, including lactate dehydrogenase (LDH), cardiac troponin I (cTnI), creatine kinase isoenzyme (CK-MB), and brain natriuretic peptide (BNP), and histopathology of the cardiomyocytes were assessed 4 weeks post DOX challenge. Serum levels of IL-1β, IL-18, superoxide dismutase (SOD), malondialdehyde (MDA) and glutathione (GSH) and the expression of pyroptosis and signaling proteins were also determined.

Results

Cardiac dysfunction was observed after the DOX challenge, as evidenced by reduced ejection fraction, increased myocardial fibrosis, and increased BNP, LDH, cTnI, and CK-MB levels (p < 0.05, N = 3–10). AS-IV attenuated DOX-induced myocardial injury. The mitochondrial morphology and structure were also significantly damaged after DOX treatment, and these changes were restored after AS-IV treatment. DOX induced an increase in the serum levels of IL-1β, IL-18, SOD, MDA and GSH as well as an increase in the expression of pyroptosis-related proteins (p < 0.05, N = 3–6). Besides, AS-IV depressed myocardial inflammatory-related pyroptosis via activation of the expressions of nuclear factor E2-related factor 2 (Nrf-2) and heme oxygenase 1 (HO-1) (p < 0.05, N = 3).

Conclusions

Our results showed that AS-IV had a significant protective effect against DOX-induced myocardial injury, which may be associated with the activation of Nrf-2/HO-1 to inhibit pyroptosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyroptosisHeart DiseasesHumansNF-E2-Related Factor 2InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinInterleukin-18Heme Oxygenase-1Oxidative StressSignal TransductionMyocytes, CardiacDoxorubicinSaponinsTriterpenes

Stichwörter der Autor:innen

Astragalus membranaceusNrf-2/HO-1cardiac dysfunctioncardioprotectiondoxorubicinpyroptosis

Substanzen

NF-E2-Related Factor 2InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinInterleukin-18Heme Oxygenase-1Doxorubicinastragaloside ASaponinsTriterpenes

Autor:innen und Institutionen

  • Affiliated Hospital of Jining Medical University, Clinical Medical College, Jining Medical University, 272000 Jining, Shandong, China.
  • Jining Key Laboratory for Diagnosis and Treatment of Cardiovascular Diseases, 272000 Jining, Shandong, China.
  • Cheeloo College of Medicine, Shandong University, 250012 Jinan, Shandong, China.

Förderung

  • Shandong Province Medical and health Science and Technology Development Program
  • National Nature Science Foundation of China
  • Jining City Science and Technology Key Research and Development Program
  • Research Fund for Academician Lin He New Medicine

Zitieren

APA

Chen, X., Tian, C., Zhang, Z., Qin, Y., Meng, R., Dai, X., Zhong, Y., Wei, X., Zhang, J., & Shen, C. (2023). Astragaloside IV Inhibits NLRP3 Inflammasome-Mediated Pyroptosis via Activation of Nrf-2/HO-1 Signaling Pathway and Protects against Doxorubicin-Induced Cardiac Dysfunction. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2803045

Vancouver

Chen X, Tian C, Zhang Z, Qin Y, Meng R, Dai X, et al. Astragaloside IV Inhibits NLRP3 Inflammasome-Mediated Pyroptosis via Activation of Nrf-2/HO-1 Signaling Pathway and Protects against Doxorubicin-Induced Cardiac Dysfunction. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2803045

BibTeX
@article{Chen2023,
  author = {Chen, Xueheng and Tian, Chao and Zhang, Zhiqiang and Qin, Yiran and Meng, Runqi and Dai, Xuening and Zhong, Yuanyuan and Wei, Xiqing and Zhang, Jinguo and Shen, Cheng},
  title = {Astragaloside IV Inhibits NLRP3 Inflammasome-Mediated Pyroptosis via Activation of Nrf-2/HO-1 Signaling Pathway and Protects against Doxorubicin-Induced Cardiac Dysfunction},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2023},
  doi = {10.31083/j.fbl2803045}
}
Kostenlos starten →